ArticleIn vivo (Athens, Greece)
The Effect of Metformin Usage in Patients With Metastatic Colorectal Cancer Receiving First-line Systemic Therapy.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.Frontiers in pharmacology · 2026Review
- Mitochondrial dysfunction as a metabolic checkpoint of immunotherapy response in colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimTo investigate the effect of metformin usage on progression-free (PFS) and overall (OS) survival in patients with metastatic colorectal cancer (mCRC) receiving first-line systemic therapy. PATIENTS AND
methodsThis was a single-center retrospective cohort study of patients aged 18 years or older with histologically confirmed mCRC receiving first-line systemic 5-fluorouracil-based chemotherapy combined with either anti-epidermal growth factor receptor (EGFR) therapy or anti-vascular endothelial growth factor (bevacizumab) between January 2010 and December 2022. This study examined the effect of metformin on PFS and OS of patients with mCRC.
resultsA total of 134 patients were included, with a median age of 59.5 years; 66.4% of the patients were male, and 23.9% had diabetes. Metformin usage was associated with a significant improvement in median PFS (14.0
conclusionMetformin usage in patients with mCRC receiving systemic therapy may improve progression-free survival but does not significantly affect overall survival. This result outlines the potential of metformin in mCRC treatment, especially in enhancing the progression-free survival. Further studies are needed to confirm the role of metformin in systemic treatment of mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.